TOP 10 FROM THE EDITOR
1.
The Next Big Thing
2.
A Family Affair
3.
Commercialization Or Bust?
4.
A Measure Of Improvement Needed
5.
The L Word
6.
The Growing Appetite For Obesity Drugs
7.
Choosing Your Battles
8.
Risky Business
9.
More Transparency, To A Point
10.
More Than A Seat At The Table
TOP 10 FEATURED ARTICLES
What Key Characteristics Or Attributes — Beyond Functional Or Scientific Expertise — Should A CEO Look For In Considering The Addition Of A New Board Member?
By Thomas Wiggans
To Advance Your Career, Cultivate Executive Presence
By Joel Garfinkle
My Journey From "Science Guy" To CEO
By Tom McCourt
What I Learned As CEO The First Time Around
By Robert Foster
What Advice Would You Give To Small Biotechs That Have Delayed Or Canceled Plans For A Public Offering, But Still Need Funding To Advance Clinical Programs?
By Pamela Reilly Contag
Essential Elements Of Becoming A Successful CEO
By Craig Tooman
Making The Jump From Big Pharma To Biotech
By Paul Lévesque
Key Questions To Ask When Entering A Pharma Partnership
By Jody Staggs
The FDA’s Final Guidance On Early-Phase Cell & Gene Therapy Trials
By Tim Sandle, Ph.D.
Why Takeda Is Focusing So Much On Plasma-Derived Therapies
By Ben Comer
TOP 10 WEB-EXCLUSIVE CONTENT
Why Do So Many Alzheimer’s Clinical Trials Fail?
By RJ Tesi, MD, INmune Bio
Pricing Strategy For New Anti-Alzheimer’s Drug Puts Access Community On The Defensive
By Nikolina Janakievski and Cheryl Nagowski
Will You Sink, Survive, Or Thrive In This Biotech Market Correction?
By Arda Ural, EY
Executives Are Eager — But Concerned — For The Future Of AI In Clinical Trials
By Will Bryant and Jason Hirschhorn, Point B
CDMO Partnerships In Early Development Aren’t Always The Best Choice
By Aisha Shakeel and Kieran Reals, PA Consulting
Decentralization: It’s More Than You Think
By Garri Zmudze, LongeVC
Where Do We Stand On Adopting Continuous Manufacturing For Biologics?
By Richard Chen, Chris Hwang, Kelvin Lee, Andrew Zydney, and John F. Kokai-Kun
Here’s A Realistic Outlook For AI In Biomanufacturing
By Camille Bilodeau, Ph.D., University of Virginia
Key Post-Pandemic Trends In Global FDA Observations For Drug Facilities
By Ajay Pazhayattil and Marzena Ingram
This Is Not The 90s' Neuroscience
By Amy Mahery, Roivant Science
TOP 10 INDUSTRY INSIGHTS
Designing Agile Manufacturing With An Integrated Drug Product Ecosystem
By Cytiva
Is It Better To Develop And Manufacture A Drug In-House Or To Outsource?
By AGC Biologics
Strategies To Achieve Successful Approval And Launch
By Catalent
Why “Off-The-Shelf” Devices Do Not Circumvent Design Controls
By Jason Miller, Kymanox Corporation
Implement Rapid Process Changes In Gene Therapy Manufacturing
By Andelyn Biosciences
Effects Of The Ongoing Pandemic On Bupivacaine HCI Supply
By Hamid Parsa, Cambrex
Taste Masking 101: Optimize Taste And Improve Patient Outcomes
By Adare Pharma Solutions
Embracing GMP Manufacturing To Meet Pharma’s Future
By Nanoform
How An AI/ML Data Strategy Can Deliver Better Business Outcomes
By Gary Shorter, IQVIA Technologies
Prescription Digital Therapeutics: When Software Is The Active Ingredient
By Shauna Swanson, Premier Consulting
